7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸

生物活性靶点体外研究体内研究 7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸试剂级价格

CAS号:189198-30-9
英文名:2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo l-5-yl]acetic acid
中文名:7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸
CBNumber:CB61261101
分子式:C25H40N2O3
分子量:416.6
MOL File:189198-30-9.mol

7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸化学性质

沸点 :604.4±55.0 °C(Predicted)
密度 :1.071
储存条件 :4°C, away from moisture
溶解度 :DMSO: 200 mg/mL (480.08 mM)
酸度系数(pKa) :4.00±0.10(Predicted)
形态 :Solid
颜色 :White to off-white

7-[(2,2-二甲基-1-氧代丙基)氨基]-2,3-二氢-4,6-二甲基-1-辛基-1H-吲哚-5-乙酸性质、用途与生产工艺

生物活性 Pactimibe sulfate (CS-505) 是一种 ACAT1/2 双重抑制剂，对于 ACAT1 的 IC50 值为 4.9 μM，对于 ACAT2 的 IC50 值为 3.0 μM。Pactimibe sulfate (CS-505) 抑制 ACAT，其 IC50 值在肝细胞中是 2.0 μM，在巨噬细胞中是 2.7 μM，在 THP-1 细胞中是 4.7 μM。Pactimibe sulfate (CS-505) 非竞争性抑制 oleoyl-CoA，Ki 是5.6 μM。此外，Pactimibe sulfate (CS-505) 明显抑制胆固醇酯的形成，IC50 是6.7 μM。Pactimibe sulfate (CS-505) 具有抗动脉粥样硬化的潜力，可降低血浆胆固醇的活性。

靶点

ACAT1

4.9 μM (IC ₅₀ )

ACAT2

3.0 μM (IC ₅₀ )

ACAT

2 μM (IC ₅₀ , in the liver)

ACAT

2.7 μM (IC ₅₀ , in macrophages)

ACAT

4.7 μM (IC ₅₀ , in THP-1 cells)

oleoyl-CoA

5.6 μM (Ki)

cholesteryl ester formation

6.7 μM (IC ₅₀ )

体外研究

Pactimibe sulfate (CS-505) induces moderate ACAT inhibition in monocyte-derived macrophages, leading to the suppression of foam cell formation.

体内研究

Pactimibe sulfate (CS-505; 60 and 200 mg/kg/day; oral gavage; twice a day; 12 weeks) induces an inhibition for ACAT-1 and ACAT-2, causing a reduction of plasma cholesterol but no influence on macrophage- or collagen-positive areas.

Animal Model:	Male C57BL/6J ApoE ^−/− mice aged 8-week-old
Dosage:	60 and 200 mg/kg/day
Administration:	Oral gavage; twice a day; 12 weeks
Result:	Decreased plasma cholesterol levels by 39% and 74% at the administration of 60 and 200 mg/kg/day.